A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders

This publication has 69 references indexed in Scilit:

• The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance
  The FASEB Journal, 2005
• Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation
  Cognitive Brain Research, 2005
• The Hypothalamic Neuropeptide Melanin-Concentrating Hormone Acts in the Nucleus Accumbens to Modulate Feeding Behavior and Forced-Swim Performance
  Journal of Neuroscience, 2005
• The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice
  Life Sciences, 2004
• Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims
  Molecular Psychiatry, 2004
• Neurobiological bases for the relation between sleep and depression
  Sleep Medicine Reviews, 2002
• Novel, Not Adenylyl Cyclase-Coupled Cannabinoid Binding Site in Cerebellum of Mice
  Biochemical and Biophysical Research Communications, 2002
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
  Published by Wiley ,2001
• Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis
  Life Sciences, 1996
• Differential Effects of Chronic Treatment with Either Dopamine D1 or D2 Receptor Agonists on the Acute Neuroendocrine Actions of the Highly Potent Synthetic Cannabinoid HU-210 in Male Rats
  Neuroendocrinology, 1995